Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Gemigliptin, a Dipeptidyl Peptidase-IV Inhibitor: A Crossover Drug-Drug Interaction Study in Healthy Male Korean Volunteers

Clinical Therapeutics

Volumn 34, Issue 5, 2012, Pages 1182-1194

  Noh, Yook Hwan ^a   Lim, Hyeong Seok ^a,b   Jin, Seok Joon ^a   Kim, Mi Jo ^a   Kim, Yo Han ^a   Sung, Hye Ryoung ^a   Choi, Hee Youn ^a   Bae, Kyun Seop ^a,b  

^a Asan Medical Center   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

CYP3A4; Drug drug interaction; Gemigliptin; Ketoconazole; LC15 0444; Rifampicin

Indexed keywords

CYTOCHROME P450 3A4; GEMIGLIPTIN; KETOCONAZOLE; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DRUG INTERACTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INTERACTION; DRUG METABOLISM; DRUG TOLERABILITY; DYSPEPSIA; ECZEMA; EYE PAIN; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MYALGIA; NORMAL HUMAN; OPEN STUDY; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; URTICARIA;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; KETOCONAZOLE; MALE; ORGANIC CHEMICALS; PIPERIDONES; PYRIMIDINES; REPUBLIC OF KOREA; RIFAMPIN; TANDEM MASS SPECTROMETRY; TIME FACTORS; YOUNG ADULT;

EID: 84860750868     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.04.001     Document Type: Article

References (27)

1. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
2. Wani J.H., John-Kalarickal J., Fonseca V.A. Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review. Cardiol Clin 2008, 26:639-648.
3. Holst J.J., Deacon C.F. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998, 47:1663-1670.
4. Lim K.S., Kim J.R., Choi Y.J., et al. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study. Clin Ther 2008, 30:1817-1830.
5. Rhee E.J., Lee W.Y., Yoon K.H., et al. A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes. Diabetes Obes Metab 2010, 12:1113-1119.
6. Lim K.S., Cho J.Y., Kim B.H., et al. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers. Br J Clin Pharmacol 2009, 68:883-890.
7. Venkatakrishnan K., von Moltke L.L., Greenblatt D.J. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000, 38:111-180.
8. Chen J., Raymond K. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob 2006, 5:3.
9. Niemi M., Kivisto K.T., Diczfalusy U., et al. Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenet Genomics 2006, 16:565-568.
10. Backman J.T., Olkkola K.T., Neuvonen P.J. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996, 59:7-13.
11. Achira M., Suzuki H., Ito K., Sugiyama Y. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. AAPS PharmSci 1999, 1:E18.
12. Niemi M., Backman J.T., Fromm M.F., et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003, 42:819-850.
13. Dresser G.K., Spence J.D., Bailey D.G. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000, 38:41-57.
14. Bjornsson T.D., Callaghan J.T., Einolf H.J., et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003, 43:443-469.
15. Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling US Food and Drug Administration, Accessed December 20, 2011. http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4079B1_04_Topic2-TabA.pdf.
16. Tanaka C., Yin O.Q., Smith T., et al. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 2011, 51:75-83.
17. ICH harmonized tripartite guideline. Guideline for Good Clinical Practice. J Postgrad Med 2001, 47:45-50.
18. The Declaration of Helsinki [in Italian]. Assist Inferm Ric 2010, 29:41-44. World Medical Association.
19. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications 2011, Lippincott Williams & Wilkins, Philadalphia, Pa. 4th ed. M. Rowland, T. Tozer (Eds.).
20. Huang S.M., Temple R., Throckmorton D.C., Lesko L.J. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 2007, 81:298-304.
21. Ohno M., Yamaguchi I., Saiki K., et al. Specific determination of urinary 6beta-hydroxycortisol and cortisol by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 2000, 746:95-101.
22. Dhillon S., Weber J. Saxagliptin. Drugs 2009, 69:2103-2114.
23. European Medicines Agency, Accessed February 14, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001039/WC500044316.pdf.
24. Fura A., Khanna A., Vyas V., et al. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos 2009, 37:1164-1171.
25. Onglyza (saxagliptin) tablets [prescribing information] 2011, Bristol-Myers Squibb, New York, NY.
26. Rosenstock J., Aguilar-Salinas C., Klein E., et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2009, 25:2401-2411.
27. Kim S.E., SoJeong Y., Shin K.-H., et al. Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers. Int J Clin Pharmacol Ther 2012, 50:17-23.